News | News By Subject | News by Disease News By Date | Search News

Melanoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Array BioPharma (ARRY) Has a Potential Blockbuster Melanoma Drug On Its Hands     2/13/2017
Two Deaths Linked to Bristol-Myers Squibb (BMY)'s Yervoy-Opdivo Combo     11/3/2016
Scancell (SCNLF) Delays Melanoma Trial 9 to 12 Months to Whip Up New Batch of Cancer Vaccine     7/7/2016
Scancell (SCNLF) Suspends Dosing in Melanoma Trial Due to Quality Issues     6/17/2016
European Commission (EC) Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) + Yervoy (Ipilimumab) Regimen, for Treatment of Advanced Melanoma     5/11/2016
Investors Unhappy as Caladrius Biosciences (CLBS) Kills Phase III Oncology Program, Lays Off 40 in SoCal     1/8/2016
Array BioPharma (ARRY) Surges as Binimetinib Meets Goals in Late-Stage Study     12/16/2015
FDA Grants Full U.S. Approval for Novartis AG (NVS)' Targeted Skin Cancer Combo     11/23/2015
FDA Approves Daiichi Sankyo, Plexxikon's Cobimetinib In Combination With Zelboraf for Advanced Melanoma Patients     11/11/2015
FDA Green Lights Genentech (RHHBY)'s Vemurafenib/Cobimetinib Combo for Melanoma     11/10/2015
Investors Elated as Amgen (AMGN) Wins FDA Approval for First-of-Its-Kind Cancer Killing Virus Drug     10/30/2015
Investors Hold Their Breath as Amgen (AMGN) Inches Toward U.S. Approval for Its New Cancer Immunotherapy T-Vec     10/26/2015
Exelixis (EXEL), Genentech (RHHBY)'s Cobimetinib Succeeds in Pivotal Phase III Trial     10/8/2015
FDA Green Lights Bristol-Myers Squibb (BMY)'s Drug Combo for Metastatic Melanoma     10/2/2015
Joining the Anti-PD-L1 Cancer Drug Market, Syndax Inks Deal With Genentech (RHHBY), Closes on $80 Million Series C Round     8/27/2015

News from Around the Web
New Technique Spots Pheomelanin In Pale Patients At Risk Of Dangerous Melanoma, Massachusetts General Hospital Reveals     3/8/2017
Genetic Causes Of Higher Melanoma Risk In Men Discovered, Universitat Jaume I de Castellón Reveals     7/22/2016
Microneedle Patch Delivers Localized Cancer Immunotherapy To Melanoma, North Carolina State University Study     3/25/2016
Pharma's Big New Cancer Drug May Be An Old Red Dye     2/26/2016
Vitamin B3 Derivative Cuts Risk Of New Skin Cancers, University of Sydney Study     10/22/2015
Could Laser Skin Test Replace Biopsy For Melanoma? Lancaster University Study     8/24/2015
Coffee Lowers Deadly Skin Cancer Risk, Yale School Of Public Health Study     1/22/2015
Sunscreens Do Not Fully Protect Against Skin Cancer, University Miguel Hernández Study     7/16/2014
Viagra Poses Cancer Risk For Men, JAMA Reveals     6/6/2014
Pine Bark Substance Could Treat Melanoma, Penn State Hershey Melanoma Center Study     5/22/2014
Link Between Viagra And Melanoma Discovered, JAMA Reveals     4/11/2014
Melanoma In Families Linked To Mutations In One Gene, University of Leeds Study     4/3/2014
Sleep Apnea Severity Predicts Aggressiveness of Melanoma, Hospital de Valme Study     9/9/2013
Gene Mutation Immortalizes Malignant Melanoma, University Duisburg-Essen Study     1/28/2013
GlaxoSmithKline (GSK)'s Melanoma Drug May Extend Survival     6/26/2012

Press Releases
Prima Biomed (PRR.AX) Receives Approval For Third Cohort Of Phase I Melanoma Trial     4/19/2017
Idera Pharma (IDRA) Advances Investigational Treatment—Intratumoral IMO-2125 In Combination With Ipilimumab - For Unmet Need In Anti-PD-1 Refractory Metastatic Melanoma     4/11/2017
Pivotal Study Results For Myriad Genetics (MYGN)’s myPATH Melanoma Test Highlighted In Two Additional Scientific Publications     4/5/2017
NewLink Genetics (NLNK) Release: Interim Phase II Data Demonstrate Robust Response Rate With Indoximod In Combination With Keytruda® (Pembrolizumab) For Patients With Advanced Melanoma At AACR Plenary     4/4/2017
Investors Sigh With Relief As Bristol-Myers Squibb (BMY)'s Immunotherapy Combo Extends Survival In Melanoma Patients     4/3/2017
Aura Biosciences Announces Initiation Of Phase Ib Clinical Trial And Receipt Of FDA Fast Track Designation For AU-011 For The Treatment Of Primary Ocular Melanoma     3/30/2017
Blue Cross Blue Shield Association Evidence Street Issues Positive Assessment Of Castle Biosciences’ Uveal Melanoma Gene Expression Test     3/29/2017
Phase II/II Clinical Trial Of Apexigen's APX005M In Combination With Pembrolizumab (Keytruda) Opens For Metastatic Melanoma Patients     3/21/2017
Castle Biosciences’ DecisionDx-Melanoma Test Shown To Be A Significant Predictor Of Distant Metastasis In Elderly Patients With Melanoma     3/20/2017
Prima Biomed (PRR.AX) Completes Recruitment For Second Patient Cohort In Melanoma Trial And Will Present At ICI Conference In Boston     3/15/2017
New Technique Spots Pheomelanin In Pale Patients At Risk Of Dangerous Melanoma, Massachusetts General Hospital Reveals     3/8/2017
Idera Pharma (IDRA) Presents Update From Ongoing Phase I Dose Escalation Clinical Trial Of Intratumoral IMO-2125 In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment At The 2017 ASCO-SITC Clinical Immuno-Oncology Symposium     2/27/2017
OncoSec Medical Granted FDA Fast Track Designation For Immunopulse IL-12 For The Treatment Of Metastatic Melanoma Following Progression On Pembrolizumab Or Nivolumab     2/27/2017
Aura Biosciences Receives FDA Clearance Of Investigational New Drug Application For Light-Activated AU-011 For The Treatment Of Ocular Melanoma     2/6/2017
Castle Biosciences Release: Study Demonstrates That Decisiondx-Melanoma Test Improves Identification Of High Risk Skin Melanoma When Used With AJCC Outcome Prediction Tool     1/23/2017

//-->